Press Releases

Date Title and Summary Additional Formats
Toggle Summary Argos Announces $1.5 Million Equity Investment by Lummy (Hong Kong), Ltd.
DURHAM, N.C., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has signed
View HTML
Toggle Summary Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir
New Manufacturing Process Utilizes Latent Viral RNA Antigens
View HTML
Toggle Summary Argos Announces Issuance of Arcelis(R) Technology Platform Patent
DURHAM, N.C. , Sept. 8, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform,
View HTML
Toggle Summary Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy
Patent Related to Strain-Independent Amplification of HIV Nucleic Acid Sequences
View HTML
Toggle Summary Argos Announces One-for-Twenty Reverse Stock Split
- Nasdaq Panel Determines to Allow Continued Listing on The Nasdaq Capital Market Subject to Certain Conditions -
View HTML
Toggle Summary Argos Announces Receipt of Milestone Payment from Lummy (Hong Kong) Co. Ltd.
DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced receipt of a $1.5
View HTML
Toggle Summary Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Amplification of RCC RNA Evaluated Using Newly Developed Techniques
View HTML
Toggle Summary Argos Obtains Option to License PD1 Checkpoint Inhibitors
- Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, 2018 at 8:30 a.m. ET - DURHAM, N.C., Feb.
View HTML
Toggle Summary Argos Provides Financial Update
DURHAM, N.C., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that TKC
View HTML
Toggle Summary Argos Provides Update on its ADAPT Trial Following Meeting with FDA
DURHAM, N.C., May 10, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® precision immunotherapy technology platform, today provided an update on the
View HTML

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

Tweets